Product Information:
AcrySof® IQ Toric IOLs


The proven performance of AcrySof® IQ Toric IOLs can allow your astigmatic cataract patients to meet their vision goals with less dependence on glasses or contacts for distance vision.1,2

More than nine out of 10 cataract patients achieve distance vision of 20/40 or better

Treat a Wide Range of Patients

AcrySof® IQ Toric IOLs offer spherical powers in half diopter increments from +6.0 D to +34.0 D and seven cylinder powers to treat 0.75 D to 4.11 D and greater of preexisting corneal astigmatism.

The Platform You Trust

AcrySof® IQ Toric IOLs are built on the industry-leading* AcrySof® IQ IOL platform offering BioMaterial, BioMechanics and BioOptics benefits for you and your patients. Plus they are designed to reduce distance-vision spectacle dependence for your astigmatic patients.1,2

Connect the dots mastering toric IOL resource center

Clinical Data Support for AcrySof® IQ Toric IOLs


Precise astigmatism correction

The majority of patients with AcrySof® IQ Toric IOL implants achieved less than 1 diopter residual refractive cylinder.

62% of patients implanted achieved ≤ 0.50 D residual refractive cylinder; 88% achieved ≤ 1.00 D.3


The majority of patients with AcrySof® IQ Toric IOL implants achieved uncorrected distance visual acuity of 20/40 or better.

94% of patients implanted achieved uncorrected distance visual acuity of 20/40 or better.1


Excellent rotational stability

Proven biomechanics and biomaterial help stabilize IOL positioning.

There were no occurrences of persistent adverse events observed in patients implanted with the AcrySof® IQ Toric IOL.

*There were five occurrences of surgical reintervention in four eyes for Model SA60TT first eye. Rates for retinal detachment/repair and surgical intervention for the IQ Toric IOL exceeded the FDA historical grid; however, the rates were not statistically significant.

The incidence rates in this table are based upon the number of eyes with an event divided by the number of eyes implanted.

No occurrences of persistent adverse events were observed in any patients implanted with the AcrySof® IQ Toric IOL.1


Toric IOL rotation and astigmatism correction

There were no occurrences of persistent adverse events observed in patients implanted with the AcrySof® IQ Toric IOL.

Rotation of toric IOLs away from their intended axis can reduce their astigmatic correction. Approximately 1 degree of off-axis IOL rotation results in a loss of up to 3.3% of IOL cylinder power. Complete loss of cylinder power occurs when the IOL is misaligned by more than 30 degrees. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation. Some clinical cases suggest encapsulation is complete within four weeks of implantation.4,5


The majority of AcrySof® IQ Toric IOL patients were within five degrees of the intended lens axis.

81.1% of patients were within 5 degrees of intended axis.3

View Important Product Information for
AcrySof® IQ Toric IOL+

ACRYSOF® IQ TORIC INTRAOCULAR LENSES IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

INDICATIONS: The AcrySof® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for distance vision.

WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate.

Optical theory suggests that high astigmatic patients (i.e., > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ Toric Cylinder Power IOLs.

Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions.

ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions.

Click here to view the AcrySof® IQ Toric IOL Directions for Use (DFU).

ACRYSOF® IQ TORIC INTRAOCULAR LENSES IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

INDICATIONS: The AcrySof® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for distance vision.

WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate.

Optical theory suggests that high astigmatic patients (i.e., > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ Toric Cylinder Power IOLs.

Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions.

ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions.

Click here to view the AcrySof® IQ Toric IOL Directions for Use (DFU).